Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ionis Pharmaceuticals (IONS) -- Ignore unavailable to you. Want to Upgrade?

To: wolfdog2 who wrote (2270)	9/4/1998 8:52:00 AM
From: Mailbu	Read Replies (1) \| Respond to of 4676

Thursday September 3, 4:29 pm Eastern Time Company Press Release "Some Biotech Stocks Can Double And Still Be Undervalued," Says Industry Authority McCamant ENGLEWOOD, N.J.--(BUSINESS WIRE)--Sept. 3, 1998--The recent blood bath on Wall Street has made many long-depressed biotechnology stocks even better values, according to long-time industry analyst Jim McCamant, Editor of the Medical Technology Stocks Letter (www.bioinvest.com). ''Clearly after Monday's selloff, there was an extremely oversold condition in the biotech sector,'' McCamant said in an interview. ''It was important for the biotech market leaders to bounce back Tuesday, and they did. It will take a rally in the leaders to get the whole group to move.'' McCamant will expand on his current thinking about the market and biotech stocks and pharmaceuticals in a rare East Coast appearance at the first Informed Investors New York/New Jersey BioPharma Stocks Forum Saturday morning Sept. 12 at the Englewood Radisson Hotel. In addition to McCamant, executives from seven public companies -- Genentech (NYSE:GNE - news), Immunomedics (NASDAQ:IMMU - news), Alteon (NASDAQ:ALTN - news), Organogenesis (AMEX:ORG - news), Inhale Therapeutics (NASDAQ:INHL - news), SunPharm (NASDAQ:SUNP - news) and AVI BioPharma (NASDAQ:AVII - news). The cost to attend is $25 prepaid, $40 at the door. The Forum will run from 8:30 a.m.-12:30 p.m. and includes a continental breakfast. Call Informed Investors at 800/992-4683 to register. Audio tapes for the full set (five cassettes) are $48.95 which includes all company presentations plus keynote speakers. Individual tapes are $18. Access Informed Investors' website at informedinvestors.com for more information. ''Several second-tier companies are particularly attractive at current prices because they are oversold and have less risk than some of the smaller companies,'' McCamant said. ''Isis (NASDAQ:ISIP - news), for example, can double from current prices and still be undervalued. AxyS (NASDAQ:AXPH - news) and ImClone Systems (NASDAQ:IMCL - news) are two others in that group. A few other stocks that are appear particularly undervalued right now are Agouron ((NASDAQ:AGPH - news) and ICOS (NASDAQ:ICOS - news). As leaders provide momentum, lower-priced companies that can move quickly include XOMA (NASDAQ:XOMA - news), Shaman (NASDAQ:SHMN - news) and Immunogen (NASDAQ:IMGN - news).'' Continuing FDA approvals, such as this week's Barr Labs' (NYSE:BRL - news) approval to market its Preven contraceptive kit and the FDA advisory panel's decision to recommend Genentech's Herceptin cancer treatment drug, will eventually lead to broader support for biotech stocks, McCamant said. Since 1993, Informed Investors has featured scores of quality companies and industry experts at its Forums. Contact: Informed Investors Steve Chanecka or Sean Finnigan, 916/448-8222 or 800/992-4683